Latest news with #MicroCapClub
Business Wire
22-04-2025
- Automotive
- Business Wire
Pioneer Power to Present at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025
FORT LEE, N.J.--(BUSINESS WIRE)-- Pioneer Power Solutions, Inc. (Nasdaq: PPSI) ('Pioneer' or the 'Company'), a leader in the design, manufacture, service and integration of distributed energy resources, power generation equipment and mobile electric vehicle ('EV') charging solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 9:00AM (Local Time - PDT). Nathan Mazurek, Chairman and CEO of Pioneer, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025 Time: 9:00AM (Las Vegas, NV Local Time PDT) Webcast: If you would like to book 1x1 investor meetings with Pioneer Power, and to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please make sure you are registered here: REGISTER 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV The Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub website is available here: HOME PAGE If you can't make the live presentation, all company presentations 'webcasts' will be available directly on the conference event platform on this link under the tab 'Agenda': AGENDA About Pioneer Power Solutions, Inc. Pioneer Power Solutions, Inc. is a leader in the design, manufacture, integration, refurbishment, service and distribution of electric power systems, distributed energy resources, power generation equipment and mobile electric charging solutions for applications in the utility, industrial and commercial markets. To learn more about Pioneer, please visit its website at e-Boost is Pioneer's portfolio of smart, mobile EV charging solutions. The Company has been aggressively marketing e-Boost to electric bus and truck manufacturers, fleet management companies, municipalities and EV infrastructure providers since its initial launch in November 2021. About Planet MicroCap Planet MicroCap is a global multimedia financial news, publishing and events company for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space. If you would like to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please register here:
Yahoo
21-04-2025
- Business
- Yahoo
Telescope Innovations to Present at the Planet MicroCap Showcase: VEGAS on April 23, 2025
Showcase is in partnership with MicroCapClub, and 1x1 meetings with Telescope COO are available on April 24, 2025 Vancouver, British Columbia--(Newsfile Corp. - April 14, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company") is a leading developer of advanced technologies and services for the global pharmaceutical and high-value chemical industries. The Company today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 2:00-2:30 PM (Local Time - PST). Chief Operating Officer, Dr. Jeffrey W. Sherman of Telescope Innovations Corp. will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClubDate: Wednesday, April 23, 2025Time: 2:00-2:30 PM (Las Vegas, NV Local Time PST)Webcast: Recent Company Highlights Telescope Innovations Advances Self-Driving Lab Deployment, Strengthening Industry Impact Telescope Innovations and Pfizer Sign Master Collaborative Research Agreement Mettler Toledo and Telescope Innovations Agree to Globally Distribute Telescope's Flagship Product, DirectInject-LC™ Telescope Innovations Commences Trading on the Frankfurt Stock Exchange Telescope Innovations Founder and CTO, Professor Jason Hein, Honoured with 2025 R. U. Lemieux Award - Telescope Innovations Second Nobel Prize Won by Telescope Innovations Advisor - Telescope Innovations If you would like to book 1x1 investor meetings with Telescope Innovations, and to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please make sure you are registered here: REGISTER 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV. If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the AGENDA tab. About Telescope Innovations Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability. About Planet MicroCap Planet MicroCap is a global multimedia financial news, publishing and events company for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space. If you would like to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please register here. Contact Name: Jeffrey W. Sherman, +1 443-454-7525Email: jeff@ To view the source version of this press release, please visit
Yahoo
21-04-2025
- Business
- Yahoo
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Company to conduct 1x1 meetings on April 24, 2025 GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion. Dr. Dritschilo's presentation will focus on providing an overview and update on the Company's ongoing Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma as well as advancements being made in the Company's Shuttle Diagnostics subsidiary which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025 Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time) Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NV Webcast: If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at 1x1@ 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at Safe Harbor Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Shuttle PharmaceuticalsAnatoly Dritschilo, and Chief Scientific Officer240-403-4212info@ Investor ContactsLytham Partners, LLCRobert Blum602-889-9700shph@
Yahoo
21-04-2025
- Business
- Yahoo
Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Company to conduct 1x1 meetings on April 24, 2025 GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer of Precision Optics, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025Time: 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time)Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NVWebcast: If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at 1x1@ 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV About Precision Optics CorporationFounded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit About Forward-Looking Statements This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. Company Contact: PRECISION OPTICS CORPORATION22 East BroadwayGardner, Massachusetts 01440-3338Telephone: 978-630-1800 Investor Contact:LYTHAM PARTNERS, LLCRobert BlumTelephone: 602-889-9700poci@ in to access your portfolio
Yahoo
17-04-2025
- Business
- Yahoo
Covalon to Present at the Planet MicroCap Showcase: VEGAS on April 23, 2025
MISSISSAUGA, Ontario, April 17, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that they will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 4:30 pm (Local Time -PST). Brent Ashton, Covalon's CEO will review why Covalon is in the "sweet spot" in the microcap sector as an undervalued, cash rich, profitable healthcare company that to date is very much undiscovered by investors. Key highlights include: Financial experts agree that healthcare is a stable and growing industry compared with other sectors Patients and healthcare providers continue to deal with unnecessary pain, suffering and even death from largely preventable complications which Covalon's advanced wound care, vascular access and surgical products address - improving lives and avoiding expensive and unnecessary treatment Covalon's sales have increased as more and more healthcare providers as well as patients themselves advocate for the use of Covalon's unique and powerful, best-in-class, patented technologies With consistent profitability, over $17 million ($CAD) of cash on hand, debt free, and strong revenue growth, Covalon is a standout for microcap investors seeking substantial returns With the Company recently being recognized as a top-performing organization as both a 2025 OTCQX Best 50 Company and TSX Venture Top 50 company, Covalon has just begun its journey as a high performing microcap public company "I'm very excited to be presenting at my second Planet Microcap Conference since joining Covalon," said Brent Ashton, Covalon's Chief Executive Officer. "The Vancouver conference last September was standing room only with an audience of mainly Canadian-based investors, and I'm looking forward to meeting with US and international investors at this event." It is clear that US investors have identified the Canadian microcap market as undervalued and the Company looks forward to discussing Covalon's significant growth opportunity in the healthcare sector – a space that is always in need regardless of where the broader macro-economic cycle sits. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025Time: 4:30 pm (Las Vegas, NV Local Time PST)Webcast: If you would like to book 1x1 investor meetings with Covalon, and to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please make sure you are registered here: REGISTER 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV To view a recent interview conducted by conference organizers with Covalon's CEO, please click here: The Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub website is available here: HOME PAGE For those who are not able to attend the conference but are interested in learning more about Covalon's solutions, visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About Covalon Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at About Planet MicroCap Planet MicroCap is a global multimedia financial news, publishing and events company for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. View source version on Contacts To learn more about Covalon, please contact:Investor Relations, Covalon Technologies investors@ Website: Sign in to access your portfolio
